The prednisolone suppression test in depression: Dose-response and changes with antidepressant treatment

Psychoneuroendocrinology

Volumn 35, Issue 10, 2010, Pages 1486-1491

  Juruena, Mario F ^a,b,c   Cleare, Anthony J ^a,b   Papadopoulos, Andrew S ^a,b   Poon, Lucia ^a,b   Lightman, Stafford ^d   Pariante, Carmine M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b BETHLEM ROYAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Cortisol; Depression; Glucocorticoid receptor; Hypothalamic pituitary adrenal (HPA) axis; Mineralocorticoid receptor; Negative feedback; Prednisolone; Treatment resistant depression

Indexed keywords

GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; MINERALOCORTICOID RECEPTOR; MOOD STABILIZER; PLACEBO; PREDNISOLONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MALE; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALIVATION; SINGLE BLIND PROCEDURE; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOCORTICOIDS; HUMANS; INPATIENTS; LINEAR MODELS; MALE; MIDDLE AGED; PREDNISOLONE; PSYCHIATRIC STATUS RATING SCALES; SALIVA;

EID: 78650169913     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2010.04.016     Document Type: Article

References (23)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Press, Washington, DC.
2. Binder E.B., Kunzel H.E., Nickel T., Kern N., Pfennig A., Majer M., Uhr M., Ising M., Holsboer F. HPA-axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressedpatients. Psychoneuroendocrinology 2009, 34:99-109.
3. Fekadu A., Wooderson S.C., Markopoulou K., Cleare A.J. The MaudsleyStaging Method for treatment-resistant depression: prediction of longer-termoutcome and persistence of symptoms. J. Clin. Psychiatry 2009, 70:952-957.
4. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured ClinicalInterview for DSM-IV Axis I Disorders-Clinician Version (SCID-CV) 1997, American Psychiatric Press.
5. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
6. Hennings J.M., Owashi T., Binder E.B., Horstmann S., Menke A., Kloiber S., Dose T., Wollweber B., Spieler D., Messer T., Lutz R., Kunzel H., Bierner T., Pollmacher T., Pfister H., Nickel T., Sonntag A., Uhr M., Ising M., Holsboer F., Lucae S. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients-findings from the Munich Antidepressant Response Signature (MARS) project. J. Psychiatr. Res. 2009, 43:215-229.
7. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J. Psychiatr. Res. 1999, 33:181-214.
8. Ising M., Horstmann S., Kloiber S., Lucae S., Binder E.B., Kern N., Kunzel H.E., Pfennig A., Uhr M., Holsboer F. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression-a potential biomarker?. Biol. Psychiatry 2007, 62:47-54.
9. Juruena M.F., Cleare A.J., Papadopoulos A.S., Poon L., Lightman S., Pariante C.M. Different responses to dexamethasone and prednisolone in the same depressed patients. Psychopharmacology (Berl.) 2006, 189:225-235.
10. Juruena M.F., Gama C.S., Berk M., Belmonte-de-Abreu P.S. Improved stress response in bipolar affective disorder with adjunctive spironolactone (mineralocorticoid receptor antagonist): case series. J. Psychopharmacol. 2009, 23:985-987.
11. Juruena M.F., Pariante C.M., Papadopoulos A.S., Poon L., Lightman S., Cleare A.J. Prednisolone suppression test in depression: prospective study of the role of HPA axis dysfunction in treatment resistance. Br. J. Psychiatry 2009, 194:342-349.
12. Juruena M.F., Pariante C.M., Papadopoulos A., Cleare A.J. The Development and Application of the Prednisolone suppression Test in Psychiatry: A novel Tool for Assessing Glucocorticoid and Mineralocorticoid Receptor Function. Mind & Brain, J. Psych. 2010, 1(1):115-122.
13. Lopez J.F., Chalmers D.T., Little K.Y., Watson S.J. A. E. Bennett Research Award. Regulation of serotonin 1A, glucocorticoid, and mineralocorticoidreceptor in rat and human hippocampus: implications for the neurobiology of depression. Biol. Psychiatry 1998, 43:547-5732.
14. Orth D., Kovacs W. The adrenal cortex. Williams Textbook of Endocrinology 1998, 517-664. W.B. Saunders Company, Philadelphia. J. Wilson, D. Foster, H. Kronenberg, P. Larsen (Eds.).
15. Otte C., Hinkelmann K., Moritz S., Yassouridis A., Jahn H., Wiedemann K., Kellner M. Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study. J. Psychiatr. Res. 2010, 44(6):339-346.
16. Owashi T., Otsubo T., Oshima A., Nakagome K., Higuchi T., Kamijima K. Relationships of DEX/CRH and GHRH test results to the outcome of depression-preliminary results suggest the GHRH test may predict relapse after discharge. J. Psychiatr. Res. 2008, 42:356-364.
17. Pariante C.M., Papadopoulos A.S., Poon L., Checkley S.A., English J., Kerwin R.W., Lightman S. A novel prednisolone suppression test for the hypothalamicpituitary-adrenal axis. Biol. Psychiatry 2002, 51:922-930.
18. Pariante C.M., Papadopoulos A.S., Poon L., Cleare A.J., Checkley S.A., English J., Kerwin R.W., Lightman S. Four days of citalopram increase suppression of cortisol secretion by prednisolone in healthy volunteers. Psychopharmacology (Berl.) 2004, 177:200-206.
19. Sackeim H.A., Prudic J., Devanand D.P., Decina P., Kerr B., Malitz S. The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J. Clin. Psychopharmacol. 1990, 10:96-104.
20. Taylor D., Paton C., Kerwin R. The South London and Maudsley NHS Trust Oxleas NHS Trust, Prescribing Guidelines 2005, Taylor & Francis, London. 8th ed.
21. Thase M.E., Rush A.J. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J. Clin. Psychiatry 1997, 58(Suppl. 13):23-29.
22. Young E.A., Lopez J.F., Murphy-Weinberg V., Watson S.J., Akil H. Mineralocorticoid receptor function in major depression. Arch. Gen. Psychiatry 2003, 60:24-28.
23. Zobel A.W., Yassouridis A., Frieboes R.M., Holsboer F. Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. Am. J. Psychiatry 1999, 156:949-951.